Welcome to our dedicated page for Landos Biopharma news (Ticker: LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma stock.
Landos Biopharma, Inc. (LABP) is a clinical-stage biotechnology company pioneering oral therapies for autoimmune diseases through innovative immunometabolic research. This page provides centralized access to official news and developments surrounding LABP's scientific advancements, clinical trials, and corporate milestones.
Investors and stakeholders will find timely updates on LABP's lead investigational drug NX-13, including Phase 2 trial progress for ulcerative colitis treatment. The curated news archive features regulatory filings, partnership announcements, and financial reports essential for informed decision-making.
Our coverage spans key developments including clinical trial outcomes, research collaborations, and strategic corporate actions. All content is verified through primary sources to ensure accuracy in reporting scientific data and business developments.
Bookmark this page for direct access to LABP's latest advancements in inflammatory bowel disease research and emerging treatment paradigms. Check regularly for updates on novel oral therapies that aim to transform autoimmune disease management.
Landos Biopharma (LABP) reported significant advancements in its drug development pipeline during Q2 2021. Following a positive FDA meeting, it initiated Phase 3 trials for omilancor in ulcerative colitis (UC) and enrolled patients in Phase 2 and Phase 1b trials for Crohn's Disease and NX-13, respectively. The company secured an $18 million upfront cash payment and up to $200 million in future milestones from a strategic agreement with LianBio. As of June 30, 2021, Landos had $115 million in cash, ensuring operational funding until late 2023.
Landos Biopharma (NASDAQ: LABP) reported promising Phase 2 results for omilancor, an oral therapy for ulcerative colitis (UC). The therapy showed efficacy and tolerability, achieving significant clinical and histological remission rates. Following a successful FDA meeting, Landos is moving forward with global pivotal Phase 3 trials. Key findings include a 55% reduction in IL-6 and nearly 90% of patients reaching remission thresholds after 36 weeks. The UC market generated $5.3 billion in 2020 and is projected to grow by over 6% annually.
Landos Biopharma (NASDAQ: LABP) announced that its Chairman and CEO, Josep Bassaganya-Riera, will present at the Raymond James Virtual Human Health Innovation Conference on June 21, 2021, at 2:00 PM EDT. The presentation will highlight Landos' innovative LANCE Advanced A.I. platform, which is focused on developing oral therapeutics for autoimmune diseases. The live webcast can be accessed on the company's website, and it will be archived for future viewing. Landos is advancing 17 programs targeting key immunometabolic pathways.
Landos Biopharma announced FDA clearance for its omilancor clinical trials in patients with mild-to-moderate active ulcerative colitis (UC). The pivotal PACIFY I and II trials will assess the efficacy of omilancor versus placebo, aiming for clinical remission at 12 and 52 weeks. The Phase 2 results showed strong efficacy and tolerability, supporting the drug's potential. This new phase will further the development of treatments for over 900,000 UC patients in the U.S., addressing a significant unmet need.
Landos Biopharma (NASDAQ: LABP) announced that its Chairman and CEO, Josep Bassaganya-Riera, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:00 AM EDT. The presentation will showcase Landos' innovative LANCE A.I. platform, which is designed to develop novel oral therapeutics for autoimmune diseases. The live webcast can be accessed on the company's website, where it will also be archived after the event.
Landos is advancing 17 development programs targeting novel immunometabolic pathways, including treatments for ulcerative colitis and Crohn's disease.
Landos Biopharma (NASDAQ: LABP) has announced the appointment of Tim M. Mayleben to its Board of Directors. With over 20 years in the life sciences sector, Mayleben brings a wealth of experience in leading development and business strategies. He previously served as CEO of Esperion Therapeutics, where he directed the launch of Nexletol™/Nexlizet™. Mayleben will also chair the Compensation Committee and serve on the Audit Committee, aiming to leverage his expertise to advance Landos' autoimmune pipeline, which includes innovative therapies targeting conditions like ulcerative colitis and Crohn’s disease.
Landos Biopharma (NASDAQ: LABP) completed its IPO, raising approximately $100 million. The company reported positive Phase 2 results for omilancor in ulcerative colitis, showing significant clinical and immunological benefits. An end-of-Phase 2 meeting with FDA is planned for Q2 2021. A collaboration with LianBio is set to potentially yield $218 million in milestone payments. Cash and equivalents as of March 31, 2021, stand at $106.4 million, expected to sustain operations through 2023. However, the company reported a net loss of $9.8 million for Q1 2021.
Landos Biopharma (NASDAQ: LABP) has entered an exclusive collaboration with LianBio for the development of omilancor and NX-13 in Greater China and selected Asian markets. Landos will receive an upfront payment of $18 million and could earn up to $200 million in milestone payments. Omilancor and NX-13 are oral therapeutics aimed at treating ulcerative colitis and Crohn's disease. The partnership is expected to expand Landos' market reach and accelerate the development of its innovative autoimmune disease pipeline.
Landos Biopharma (NASDAQ: LABP) has initiated a Phase 2 study for omilancor, an innovative oral therapy for moderate-to-severe Crohn's disease (CD). The trial aims to evaluate the safety and efficacy of omilancor in approximately 150 participants over a 30-week period. Key endpoints include clinical remission and adverse event frequency. The company anticipates topline results in Q2 2022, emphasizing the need for effective treatments in the more than 100,000 patients affected by CD worldwide. Omilancor is positioned to provide a safer, gut-restricted treatment option.
Landos Biopharma (NASDAQ: LABP) has initiated a Phase 1b clinical trial for NX-13, a novel NLRX1 agonist aimed at treating ulcerative colitis (UC). This first-in-class product is designed to enhance immune tolerance and reduce inflammation in patients. The randomized, double-blind study will evaluate 40 subjects over 28 days with results expected in Q1 2022. Previous Phase 1a trials indicated a maximum tolerated dose significantly higher than anticipated, hinting at NX-13's potential efficacy. Landos also plans further trials for Crohn’s disease and other autoimmune conditions.
